Donald J Pinto
Overview
Explore the profile of Donald J Pinto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Raghavan N, He K, Luettgen J, Humphreys W, Knabb R, et al.
Drug Metab Dispos
. 2009 Jan;
37(4):802-8.
PMID: 19131519
Apixaban, a potent and highly selective factor Xa inhibitor, is currently under development for treatment of arterial and venous thrombotic diseases. The O-demethyl apixaban sulfate is a major circulating metabolite...
2.
He K, Qian M, Wong H, Bai S, He B, Brogdon B, et al.
J Pharm Sci
. 2007 Oct;
97(7):2568-80.
PMID: 17914718
N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug-drug interactions this...
3.
Pieniaszek Jr H, Davidson A, Walton H, Pinto D, Olson R, Reilly T, et al.
J Pharm Biomed Anal
. 2002 Dec;
30(5):1441-9.
PMID: 12467915
A radioimmunoassay (RIA) was developed for the determination of XV459, the active hydrolysis metabolite of the oral prodrug roxifiban (DMP 754), in human plasma. XV459 is a potent antagonist of...
4.
Mutlib A, Shockcor J, Chen S, Espina R, Pinto D, Orwat M, et al.
Chem Res Toxicol
. 2002 Jan;
15(1):48-62.
PMID: 11800597
The in vitro and in vivo disposition of DPC 423 was investigated in mice, rats, dogs and humans and the metabolites characterized by LC/MS, LC/NMR and high field-NMR. The rodents...